JP2024525723A - インターロイキン-23受容体の二環式ペプチド阻害剤 - Google Patents

インターロイキン-23受容体の二環式ペプチド阻害剤 Download PDF

Info

Publication number
JP2024525723A
JP2024525723A JP2024501737A JP2024501737A JP2024525723A JP 2024525723 A JP2024525723 A JP 2024525723A JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024525723 A JP2024525723 A JP 2024525723A
Authority
JP
Japan
Prior art keywords
alkyl
phe
cyano
interleukin
bicyclic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525723A5 (cg-RX-API-DMAC7.html
Inventor
サン,チェンザオ
ニーランカヴィル,サントーシュ
パッチ,レイモンド,ジェイ.
ソマニ,サンディープ
バロス,ステファニー,エー.
ジャン,ジン
ヘンドリック,チャールズ
ビアンキ,エリザベッタ
コスタンテ,ロベルト
インジェニート,ラファエル
ブランカ,ダニラ
バンダリ,アショク
フレデリック,ブライアン
チュン チャン,チャン
ジャン,ジエ
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
プロタゴニスト セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド, プロタゴニスト セラピューティクス, インコーポレイテッド filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2024525723A publication Critical patent/JP2024525723A/ja
Publication of JP2024525723A5 publication Critical patent/JP2024525723A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
JP2024501737A 2021-07-14 2022-07-14 インターロイキン-23受容体の二環式ペプチド阻害剤 Pending JP2024525723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14
US63/221,854 2021-07-14
PCT/US2022/037202 WO2023288017A2 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024525723A true JP2024525723A (ja) 2024-07-12
JP2024525723A5 JP2024525723A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501737A Pending JP2024525723A (ja) 2021-07-14 2022-07-14 インターロイキン-23受容体の二環式ペプチド阻害剤

Country Status (12)

Country Link
US (1) US20240352073A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370532A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525723A (cg-RX-API-DMAC7.html)
KR (1) KR20240034223A (cg-RX-API-DMAC7.html)
CN (1) CN117980320A (cg-RX-API-DMAC7.html)
AR (1) AR126457A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022310347A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226492A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000761A (cg-RX-API-DMAC7.html)
TW (1) TW202321275A (cg-RX-API-DMAC7.html)
UY (1) UY39858A (cg-RX-API-DMAC7.html)
WO (1) WO2023288017A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011820A2 (en) * 2015-07-15 2017-01-19 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20170033372A (ko) * 2014-07-17 2017-03-24 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
US20180105572A1 (en) * 2014-10-01 2018-04-19 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2020513412A (ja) * 2016-12-06 2020-05-14 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021019246A1 (en) * 2019-07-30 2021-02-04 Bicycletx Limited Heterotandem bicyclic peptide complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170033372A (ko) * 2014-07-17 2017-03-24 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
US20180105572A1 (en) * 2014-10-01 2018-04-19 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2017011820A2 (en) * 2015-07-15 2017-01-19 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2020513412A (ja) * 2016-12-06 2020-05-14 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021019246A1 (en) * 2019-07-30 2021-02-04 Bicycletx Limited Heterotandem bicyclic peptide complexes

Also Published As

Publication number Publication date
EP4370532A4 (en) 2025-09-03
KR20240034223A (ko) 2024-03-13
TW202321275A (zh) 2023-06-01
CN117980320A (zh) 2024-05-03
AR126457A1 (es) 2023-10-11
UY39858A (es) 2023-02-28
WO2023288017A3 (en) 2023-03-09
MX2024000761A (es) 2024-04-18
US20240352073A1 (en) 2024-10-24
WO2023288017A2 (en) 2023-01-19
AU2022310347A1 (en) 2024-02-29
CA3226492A1 (en) 2023-01-19
EP4370532A2 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
EP4370531A2 (en) Peptide inhibitors of interleukin-23 receptor
AU2022310347A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
JP7441955B2 (ja) インターロイキン23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP7670605B2 (ja) インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP2025134806A (ja) インターロイキン23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2022540154A (ja) インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2023014346A (ja) インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
HK40111925A (en) Lipidated peptide inhibitors of interleukin-23 receptor
CN121335914A (zh) 白介素-23受体的肽抑制剂
HK40083331A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609